A Short and Long Intravenous Infusion Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-962212 in Healthy Subjects

Model scores of the 29,894 trials active now.

Model score 12% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 7% of the time (318 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2017-01-24. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: and pharmacodynamicsascendingtolerability pharmacokineticssafety tolerabilitypharmacokinetics and
  Phrases that lowered it: healthykgclinical trialto evaluateparticipants
• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Sponsor's past termination rate: 10.4% (raises risk) · Sponsor's track record
• Phase: 1 (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 100 (lowers risk) · Sponsor's track record
• Blinding: double (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 16849 (lowers risk) · Drug's FDA history
• Drug's FAERS reports with a death: 9.9% (lowers risk) · Drug's FDA history
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports before start: 158967 (lowers risk) · Drug's FDA history
• Number of arms: 5 (lowers risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Maximum age: 45 (lowers risk) · Who can join
• Keywords listed: 0 (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study of Experimental Medication BMS-986235 in Healthy Subjects NCT03335553 · started 2017 · scored riskier than 7% of active trials completed
• Study to Evaluate the Safety, Pharmacokinetics and Target Engagement of BMS-986142 in Healthy Subjects NCT02257151 · started 2014 · scored riskier than 6% of active trials completed
• A Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of Single and Multiple Doses of BMS-986209 in Healthy Participants NCT04154800 · started 2019 · scored riskier than 8% of active trials completed
• A Multiple Dose Study to Assess the Safety and Tolerability of BMS-986166 in Healthy Volunteers NCT03038711 · started 2017 · scored riskier than 6% of active trials completed
• Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects NCT02341638 · started 2014 · scored riskier than 10% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.